MedTrace Logo

REBEAT Resynchronisation and Beta-Blocker European Trial

NCT00305526 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 354

Last updated 2007-08-09

No results posted yet for this study

Summary

This protocol will evaluate the effect of cardiac resynchronization therapy (CRT) combined with beta-blocker therapy in patients with symptomatic heart failure in whom beta-blocker therapy was either not tolerated or could not be up titrated to optimal doses before CRT. Cardiac resynchronization therapy will be combined with automatic implantable cardioverter defibrillator (AICD, CRT-D) as it has been shown to be associated with an improvement in prognosis in the patients with left ventricular systolic dysfunction and heart failure.

Conditions

Interventions

DEVICE

Contak Renewal (CRT-D)

Sponsors & Collaborators

  • Guidant Corporation

    lead INDUSTRY

Principal Investigators

  • Antonio Curnis, MD · Spedali Civili di Brescia, Brescia, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Completion
2007-07-31

Countries

  • Italy
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00305526 on ClinicalTrials.gov